ClinicalTrials.gg
WithdrawnNCT07357766Updated Jul 9, 2026

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

A Phase 3 interventional study of Cagrisema and Placebo CagriSema in Overweight and Obesity, sponsored by Novo Nordisk A/S. Withdrawn at 116 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was withdrawn
The study is withdrawn due to strategic reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
36th of 36
0 · median 154
Started
2026
with 9 others
Phase 3
15 of 36
4 open now
Registered
28th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 36th largest by enrollment, is one of 10 that started in 2026, is one of 15 in phase 3, and was the 28th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (sex at birth)
  • Age 18 years or above at the time of signing the informing consent.
  • (BMI) is greater than or equal to (>= ) 30.0 kilograms per square metre (kg/m\^2) or BMI >= 27.0 kg/m\^2 with the presence of at least one obesity-related complication including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.

Exclusion criteria

Exclusion Criteria:

  • Glycosylated () >= 6.5 % (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening.
  • History of type 1 or type 2 diabetes.
  • Previous exposure to CagriSema in a clinical study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CagriSema B in device 2 + Placebo in device 1

    Participants will receive CagriSema B in device 2 followed by placebo matched to CagriSema in device 1 subcutaneously once weekly in a dose escalation manner for 16 weeks until the target maintenance dose and further continue to receive the same dose for up to 44 weeks.

    Drug: Cagrisema

  • Experimental
    CagriSema in device 1 + Placebo in device 2

    Participants will receive CagriSema in device 1 followed by placebo matched to CagriSema B in device 2 subcutaneously once weekly in a dose escalation manner for 16 weeks until the target maintenance dose and further continue to receive the same dose for up to 44 weeks.

    Drug: Cagrisema

  • Placebo comparator
    Placebo in device 1 + Placebo in device 2

    Participants will receive placebo matched to Cagrisema in device 1 followed by placebo matched to CagriSema B in device 2 subcutaneously once weekly for up to 44 weeks.

    Drug: Placebo CagriSema

Interventions

  • Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.

  • DrugPlacebo CagriSema

    Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Relative change in body weight

    Measured in percentage (%).

    Time frame: From baseline (week 0) to end of treatment (week 44)

Secondary outcomes

  1. Number of TEAEs (treatment emergent adverse events)

    Measured in count of events.

    Time frame: From baseline (week 0) to end of study (week 51)

  2. Number of TESAEs (Treatment emergent serious adverse events)

    Measured in count of events.

    Time frame: From baseline (week 0) to end of study (week 51)

08

Study locations

116 sites
  • Uni of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Cahaba Research
    Pelham, Alabama 35124, United States
  • Advanced Investigative Medicine, Inc.
    Hawthorne, California 90250, United States
  • Southern Cal Clinical Research
    Santa Ana, California 92701, United States
  • Encompass Clinical Research_Spring Valley
    Spring Valley, California 91978, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • NextPhase Research
    Hollywood, Florida 33024, United States
  • Oceane 7 Medical & Research Center, Inc.
    Miami, Florida 33144, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • EBGS Clinical Research Center, LLC
    Snellville, Georgia 30078, United States
  • Rophe Adult & Pediatric Medicine
    Union City, Georgia 30291, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • PGM Research of Christie Clinic
    Champaign, Illinois 61822, United States
  • Arcturus HC PLC Troy Med Res
    Troy, Michigan 48098, United States
  • Anointed Nephrology & HTN, LLC
    Brookhaven, Mississippi 39601, United States
  • Palm Research Center Inc.
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Inc.
    Las Vegas, Nevada 89148, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Alliance for Multispecialty Research
    Norman, Oklahoma 73069, United States
  • Tribe Clinical Research LLC
    Greer, South Carolina 29650, United States
  • Walker Family Care
    Little River, South Carolina 29566, United States
  • Elligo Clin Res Centre
    Austin, Texas 78704, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390-9302, United States
  • Forefront Med Res Inst PLLC
    Harlingen, Texas 78550, United States
  • TPMG Clinical Research
    Newport News, Virginia 23606, United States
  • Capital Clin Res Ctr,LLC
    Olympia, Washington 98502, United States
  • IPSMC - Dr. Nikolay Kostadinov EOOD
    Burgas, 8000, Bulgaria
  • Medical Center Viva Feniks OOD
    Dobrich, 9300, Bulgaria
  • IPSOMC Dr. Miglena Rizova Ltd.
    Kyustendil, 2500, Bulgaria
  • UMHAT Pulmed OOD - Plovdiv, Department of Endocrinology
    Plovdiv, 4002, Bulgaria
  • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Endocrinology
    Plovdiv, 4002, Bulgaria
  • MHAT Sveta Karidad EAD
    Plovdiv, 4004, Bulgaria
  • DCC Iztok EOOD
    Plovdiv, 4006, Bulgaria
  • Medical Centre Razgrad OOD
    Razgrad, 7200, Bulgaria
  • DCC VII - Sofia EOOD, Endocrinology
    Sofia, 1233, Bulgaria
  • Diagnostic-Consultative Anti-Aging and Rejuvenation Center Hill Clinic EAD
    Sofia, 1618, Bulgaria
  • Medical Center Medical Plus EOOD
    Varna, 9000, Bulgaria
  • DCC Mladost - M Varna OOD
    Varna, 9009, Bulgaria
  • AIPSMC Dr. Artin Magardichyan EOOD
    Varna, 9020, Bulgaria
  • Sanos Clinic - Vejle
    Vejle, Region Syddanmark 7100, Denmark
  • Sanos Clinic - Gandrup
    Gandrup, 9362, Denmark
  • Regionshospitalet Viborg - Karkirurgisk Afsnit
    Viborg, 8800, Denmark
  • 251 Air Force General Hospital - Department of Endocrinology & Diabetes
    Athens, 11525, Greece
  • General Hospital Of Athens G Gennimatas - Department of Endocrinology
    Athens, 11527, Greece
  • Laiko General Hospital Of Athens - A' Propaedeutic Clinic of Internal Medicine-Diabetes Centre
    Athens, 11527, Greece
  • Athens Medical Center S.A. (Iatriko Athinon) - Diabetes and Obesity Unit
    Marousi, 15125, Greece
  • Athens Medical Center S.A. (Iatriko P. Falirou) - Diabetes and Clinical Research Center
    Palaió Fáliro, 17562, Greece
  • General Hospital Of Thessaloniki G Gennimatas - Internal Medicine Clinic
    Thessaloniki, 546 35, Greece
  • Thermi Clinic S.A. - Diabetes and Internal Medicine Department
    Thessaloniki, 57001, Greece
  • Arina Trial Research Kft.
    Orosháza, Bekes County 5900, Hungary
  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ
    Szeged, Csongrád-Csanád 6725, Hungary
  • Belinus Bt.
    Debrecen, Hajdú-Bihar 4025, Hungary
  • Debreceni Egyetem
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Borbánya Praxis E.Ü. Kft.
    Nyíregyháza, Szabolcs-Szatmar Varmegye 4405, Hungary
  • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.
    Budapest, 1089, Hungary
  • Hospital Raja Perempuan Zainab II
    Kota Bharu, Kelantan 15586, Malaysia
  • Hospital Canselor Tuanku Muhriz UKM
    Cheras, Kuala Lumpur 56000, Malaysia
  • University Malaya Medical Centre
    Lembah Pantai, Kuala Lumpur 59100, Malaysia
  • Hospital Seri Manjung
    Seri Manjung, Perak 32040, Malaysia
  • Hospital Pulau Pinang
    George Town, Pulau Pinang 10990, Malaysia
  • Hospital Miri
    Miri, Sarawak 98000, Malaysia
  • Klinik Kesihatan Kuang
    Rawang, Selangor 48050, Malaysia
  • University Technology MARA (UiTM) - Sg Buloh
    Sungai Buloh, Selangor 47000, Malaysia
  • Klinik Kesihatan Kuala Kedah
    Kuala Kedah, 05460, Malaysia
  • Hospital Melaka
    Malacca, 75400, Malaysia
  • Hospital Queen Elizabeth II
    Sabak Bernam, 88300, Malaysia
  • Gabinet Leczenia Otylosci i Chorob Dietozaleznych
    Bialystok, 15-281, Poland
  • Centrum Medyczne Kermed Renata Bijata-Bronisz I Ewa Kowalinska Sp. j.
    Bydgoszcz, 85-231, Poland
  • Niepubliczny Zakład Opieki Zdrowotnej BIF-MED S.C. Arkadiusz Wawiernia, Mariola Roykiewicz, Rafał Roykiewicz
    Bytom, 41-902, Poland
  • NZOZ Mediart Centrum Zdrowia Matarnia
    Gdansk, 80-298, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Gdansku
    Gdansk, 80-382, Poland
  • ID Clinic Arkadiusz Pisula
    Mysłowice, 41-400, Poland
  • Clinical Best Solutions Sp. z o.o., Sp. k
    Warsaw, 00-710, Poland
  • Synexus Polska Sp. z o.o. Oddzial w Warszawie
    Warsaw, 02-672, Poland
  • Kardio Life - Tomasz Borkowski
    Włocławek, 87-800, Poland
  • Velocity Nova Sp. z o.o.
    Zamość, 22-400, Poland
  • Prywatna Praktyka Lekarska Anna Chudoba
    Żyrardów, 96-300, Poland
  • ULS De Braga, E.P.E. - Hospital de Braga_Centro Clínico Académico
    Braga, 4710-243, Portugal
  • ULS Do Alto Ave, E.P.E - HSOG_Centro de Investigação Clínica
    Guimarães, 4835-044, Portugal
  • Hospital São Francisco, S.A_EECC
    Leiria, 2400-110, Portugal
  • APDP - Associação Protectora dos Diabéticos de Portugal
    Lisbon, 1250-189, Portugal
  • Affidea Montijo - UCardio
    Montijo, 2870-100, Portugal
  • Cardiolima Centro Diagnostico Cardio-Pulmonar De Ponte De Lima Lda
    Ponte de Lima, 4990-029, Portugal
  • Thera Card S.R.L
    Brasov, 500102, Romania
  • Kilostop Junior SRL
    Bucharest, 010073, Romania
  • SC Diamed Obesity SRL
    Galati, 800291, Romania
  • Arcadia Policlinic SRL
    Iași, 700620, Romania
  • Spital Judetean De Urgenta Satu Mare
    Satu Mare, 440055, Romania
  • SC Gensan SRL, Policlinica ASTRA
    Sibiu, 550371, Romania
  • Spitalul Clinic Judetean De Urgenta Targu Mures
    Târgu Mureş, 540136, Romania
  • MED-CENTRUM, s.r.o.
    Martin, 036 01, Slovakia
  • KARDIOMED NZ, s.r.o.
    Nové Zámky, 940 01, Slovakia
  • SVAJDLEROVA, s.r.o.
    Prešov, 080 01, Slovakia
  • ENRIN, s.r.o.
    Rimavská Sobota, 979 01, Slovakia
  • DIAB s.r.o.
    Rožňava, 04801, Slovakia
  • Soweto Clinical Trial Centre
    Johannesburg, Gauteng 1818, South Africa
  • Ezintsha Research Centre
    Johannesburg, Gauteng 2193, South Africa
  • Dr A Jacovides and Partners Inc
    Midrand, Gauteng 1685, South Africa
  • Dr Vawda's site
    Durban, KwaZulu-Natal 4091, South Africa
  • Dr T Padayachee
    Durban, KwaZulu-Natal 4170, South Africa

Showing the first 100 of 116 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisktrials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Nov 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 22, 2026
StartEst.
Jun 22, 2026
Primary completionEst.
Nov 29, 2027
CompletionEst.
Jan 17, 2028
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07357766
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Jun 22, 2026 (estimated)
Primary completion
Nov 29, 2027 (estimated)
Completion
Jan 17, 2028 (estimated)
Last update
Jul 9, 2026

Study contacts

Clinical Transparency dept. 2834
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion